Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

H C Gerstein, Hertzel C. Gerstein, Salim Yusuf, Jackie Bosch, Janice Pogue, Patrick Sheridan, M Hanefeld, M Hanefeld, B Hoogwerf, Markku Laakso, Viswanathan Mohan, J.E. Shaw, Bernard Zinman

The Lancet

September 1, 2006

10.1016/s0140-6736(06)69420-8

Cited by 1,714

Abstract

Related Papers

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

The Heart Outcomes Prevention Evaluation Study Investigators|New England Journal of Medicine|2000|8.7k

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

Jean‐Louis Chiasson, Robert G. Josse, Ramón Gomis et al.|The Lancet|2002|2.5k

The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)

Ambady Ramachandran, Chamukuttan Snehalatha, S. Mary et al.|Diabetologia|2006|1.9k

Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women

Thomas A. Buchanan, Anny H. Xiang, Ruth Peters et al.|Diabetes|2002|1.3k

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

Nigel Unwin, J.E. Shaw, Paul Zimmet et al.|Diabetic Medicine|2002|1.1k